Circulation. 2020;141:e139-e596. doi:10.1161/CIR.0000000000000757 
 
   5. Solomon S, Rizkala A, Gong J, et al. Angiotensin receptor neprilysin 
      inhibition in heart failure with preserved ejection fraction: rationale 
      and design of the PARAGON-HF trial. JACC Heart Fail. 2017;5(7):471-482. 
      doi:10.1016/j.jchf.2017.04.013 
 
   6. Solomon S, McMurray J, Anand I, et al. Angiotensin-neprilysin in heart 
      failure with preserved ejection fraction. N Engl J Med. 
      2019;381:1609-1620. doi:10.1056/NEJMoa1908655 
 
   7. Gheorghiade M, De Luca L, Fonarow G, et al. Pathophysiologic targets in 
      the early phase of acute heart failure syndromes. Am J Cardiol. 
      2005;96(6A):11G-17G. 
 
   8. Dharmarajan K, Hsieh A, Lin Z, et al. Diagnoses and timing of 30-day 
      readmissions after hospitalization for heart failure, acute myocardial 
      infarction, or pneumonia. JAMA. 2013;309(4):355-363. 
      doi:10.1001/jama.2012.216476 
 
   9. Bueno H, Ross J, Wang Y, et al. Trends in length of stay and short-term 
      outcomes among Medicare patients hospitalized for heart failure: 
      1993-2008. JAMA. 2010;303(21):2141-2147. doi:10.1001/jama.2010.748 
 
  10. EMA. Entresto (sacubitril/valsartan). Summary of product characteristics. 
      Accessed July 
      2019. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product 
      _Information/human/004062/WC500197536.pdf 
 
  11. Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with 
      LCZ696: a novel approach for the treatment of heart failure. Drug Discov 
      Today. 2012;9(4):e131-e139. doi:10.1016/j.ddstr.2013.11.002 
      https://c212.net/c/link/?t=0&l=en&o=2405309-1&h=457207487&u=http%3A%2F%2Fdx.doi.org%2F10.1016%2Fj.ddstr.2013.11.002&a=http%3A%2F%2Fdx.doi.org%2F10.1016%2Fj.ddstr.2013.11.002 
 
 
 
   # # # 
 
   Novartis Media Relations 
 
   E-mail: media.relations@novartis.com 
 
 
 
 
Anja von Treskow                        Phil McNamara 
 Novartis External Communications        Global Head, Cardio-Renal-Metabolism Communications 
 +41 61 324 2279 (direct)                +41 79 510 8756 (mobile) 
 E-mail: anja.von_treskow@novartis.com   E-mail: phil.mcnamara@novartis.com 
 Julie Masow 
 Novartis US External Communications 
 +1 862 579 8456 
 Julie.masow@novartis.com 
 
   Novartis Investor Relations 
 
   Central investor relations line: +41 61 324 7944 
 
   E-mail: investor.relations@novartis.com 
 
 
 
 
Central                                  North America 
Samir Shah              +41 61 324 7944  Sloan Simpson  +1 862 778 5052 
Thomas Hungerbuehler   +41 61 324 8425 
 Isabella Zinck         +41 61 324 7188

(END) Dow Jones Newswires

February 16, 2021 13:22 ET (18:22 GMT)